Comparison of selective ET A and ET B receptor antagonists in patients with chronic heart failure

European Journal of Heart Failure

Volumn 7, Issue 1, 2005, Pages 37-42

  Cowburn, Peter J ^a   Cleland, John G F ^b   McDonagh, Theresa A ^c   McArthur, John D ^d   Dargie, Henry J ^e   Morton, James J ^e  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d WESTERN INFIRMARY   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Endothelins; Heart failure; Pulmonary circulation

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIURETIC AGENT; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE;

ADULT; ARTICLE; BRADYCARDIA; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; DYSPNEA; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; HYPOTENSION; INFUSION; LUNG BLOOD VESSEL; LUNG CAPILLARY PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECEPTOR BLOCKING; SIDE EFFECT; VASOCONSTRICTION; VASODILATATION;

AGED; DRUG THERAPY, COMBINATION; ENDOTHELIN-1; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PIPERIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B;

EID: 11844304145     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2004.08.001     Document Type: Article

References (35)

1. M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, and Y. Mitsui A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 6163 1988 411 415
2. W.L. Miller, M.M. Redfield, and J.C. Burnett Jr. Integrated cardiac, renal, and endocrine actions of endothelin J. Clin. Invest. 83 1 1989 317 320
3. J.G. Clarke, N. Benjamin, S.W. Larkin, D.J. Webb, G.J. Davies, and A. Maseri Endothelin is a potent long-lasting vasoconstrictor in men Am. J. Physiol. 257 6 Pt. 2 1989 H2033 H2035
4. A. Lerman, F.L. Hildebr Jr., L.L. Aarhus, and J.C. Burnett Jr. Endothelin has biological actions at pathophysiological concentrations Circulation 83 5 1991 1808 1814
5. P.J. Cowburn, J.G. Cleland, J.D. McArthur, M.R. MacLean, H.J. Dargie, and J.J. McMurray Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction Cardiovasc. Res. 39 3 1998 563 570
6. M. Hiroe, Y. Hirata, N. Fujita, S. Umezawa, H. Ito, and M. Tsujino Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy Am. J. Cardiol. 68 10 1991 1114 1115
7. J.J. McMurray, S.G. Ray, I. Abdullah, H.J. Dargie, and J.J. Morton Plasma endothelin in chronic heart failure Circulation 85 4 1992 1374 1379
8. R.J. Cody, G.J. Haas, P.F. Binkley, Q. Capers, and R. Kelley Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure Circulation 85 2 1992 504 509
9. C.M. Wei, A. Lerman, R.J. Rodeheffer, C.G. McGregor, R.R. Brandt, and S. Wright Endothelin in human congestive heart failure Circulation 89 4 1994 1580 1586
10. F. Pousset, R. Isnard, P. Lechat, H. Kalotka, A. Carayon, and G. Maistre Prognostic value of plasma endothelin-1 in patients with chronic heart failure Eur. Heart J. 18 2 1997 254 258
11. P.J. Cowburn, and J.G. Cleland Endothelin antagonists for chronic heart failure: do they have a role? Eur. Heart J. 22 19 2001 1772 1784
12. G. De Nucci, R. Thomas, P. D'Orleans-Juste, E. Antunes, C. Walder, and T.D. Warner Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor Proc. Natl. Acad. Sci. U. S. A. 85 24 1988 9797 9800
13. W.G. Haynes, and D.J. Webb Endothelium-dependent modulation of responses to endothelin-I in human veins Clin. Sci. 84 4 1993 427 433
14. M.P. Love, W.G. Haynes, G.A. Gray, D.J. Webb, and J.J. McMurray Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors Circulation 94 9 1996 2131 2137
15. T. Fukuroda, T. Fujikawa, S. Ozaki, K. Ishikawa, M. Yano, and M. Nishikibe Clearance of circulating endothelin-1 by ETB receptors in rats Biochem. Biophys. Res. Commun. 199 3 1994 1461 1465
16. J. Dupuis, C.A. Goresky, and A. Fournier Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors J. Appl. Physiol. 81 4 1996 1510 1515
17. W. Kiowski, G. Sutsch, P. Hunziker, P. Muller, J. Kim, and E. Oechslin Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure Lancet 346 8977 1995 732 736
18. G. Torre-Amione, J.B. Young, J. Durand, B. Bozkurt, D.L. Mann, and I. Kobrin Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure Circulation 103 7 2001 973 980
19. P.J. Cowburn, J.G. Cleland, J.D. McArthur, M.R. MacLean, J.J. McMurray, and H.J. Dargie Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure Lancet 352 9123 1998 201 202
20. M.M. Givertz, W.S. Colucci, T.H. LeJemtel, S.S. Gottlieb, J.M. Hare, and M.T. Slawsky Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure Circulation 101 25 2000 2922 2927
21. L.E. Spieker, V. Mitrovic, G. Noll, R. Pacher, M.R. Schulze, and J. Muntwyler Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators J. Am. Coll. Cardiol. 35 7 2000 1745 1752
22. M.P. Love, W.G. Haynes, G.A. Gray, D.J. Webb, J.J. McMurray, and J.J. Vasodilator Effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors Circulation 94 9 1996 2131 2137
23. P.J. Cowburn, J.G. Cleland, J.D. McArthur, M.R. MacLean, J.J. McMurray, and H.J. Dargie Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction J. Am. Coll. Cardiol. 33 4 1999 932 938
24. M.P. Love, C.J. Ferro, W.G. Haynes, C. Plumpton, A.P. Davenport, and D.J. Webb Endothelin receptor antagonism in patients with chronic heart failure Cardiovasc. Res. 47 2000 166 172
25. F.E. Strachan, J.C. Spratt, I.B. Wilkinson, N.R. Johnston, G.A. Gray, and D.J. Webb Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men Hypertension 33 1 Pt. 2 1999 581 585
26. M. Ihara, K. Noguchi, T. Saeki, T. Fukuroda, S. Tsuchida, and S. Kimura Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor Life Sci. 50 4 1992 247 255
27. K. Ishikawa, M. Ihara, K. Noguchi, T. Mase, N. Mino, and T. Saeki Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788 Proc. Natl. Acad. Sci. U. S. A. 91 11 1994 4892 4896
28. M.C. Verhaar, F.E. Strachan, D.E. Newby, N.L. Cruden, H.A. Koomans, and T.J. Rabelink Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade Circulation 97 8 1998 752 756
29. A. Wada, T. Tsutamoto, D. Fukai, M. Ohnishi, K. Maeda, and T. Hisanaga Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure J. Am. Coll. Cardiol. 30 5 1997 1385 1392
30. M. Ohnishi, A. Wada, T. Tsutamoto, D. Fukai, and M. Kinoshita Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure Cardiovasc. Res. 39 3 1998 617 624
31. L.E. Spieker, and T.F. Luscher Endothelin receptor antagonists in heart failure-a refutation of a bold conjecture? Eur. J. Heart Fail. 5 4 2003 415 417
32. G. Cotter, E. Kaluski, K. Stangl, R. Pacher, C. Richter, and O. Milo-Cotter The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure Eur. J. Heart Fail. 6 5 2004 601 609
33. G. Sutsch, W. Kiowski, X.W. Yan, P. Hunziker, S. Christen, and W. Strobel Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure Circulation 98 21 1998 2262 2268
34. T.F. Luscher, F. Enseleit, R. Pacher, V. Mitrovic, M.R. Schulze, and R. Willenbrock Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT) Circulation 106 21 2002 2666 2672
35. J.G. Cleland, and S. Puri Pulmonary circulation and left heart disease. Left heart failure: functional aspects A.J. Peacock Pulmonary Circulation 1996 A.D. Chapman and Hall Medical London 213 234